- Question from Mona: Were any updates to the HERA trial presented?
- Answers - Ruth Oratz, M.D., F.A.C.P. We were awaiting an important update to the HERA trial, which was an internationally conducted clinical study of the use of Herceptin (chemical name: trastuzumab) following chemotherapy for patients with HER2-positive breast cancer. In the HERA trial, women were randomized to receive either no trastuzumab or 1 year of trastuzumab therapy or 2 years of trastuzumab therapy. To date, the study has demonstrated that the use of trastuzumab was superior in efficacy to the use of chemotherapy alone without trastuzumab. However, we are still awaiting results regarding the duration of treatment, and the question of whether 2 years of trastuzumab treatment is superior to 1 year, or the same, or inferior remains unanswered. There was no update at this meeting about the duration of trastuzumab treatment in the adjuvant setting.
On Wednesday, December 17, 2008, our Ask-the-Expert Online Conference was called Updates from the 2008 San Antonio Breast Cancer Symposium. Ruth Oratz, M.D., F.A.C.P. and Carol Kaplan, M.D. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.